More than reimbursing the government of the P1.4-billion unused stock of Dengvaxia vaccine, French pharmaceutical giant Sanofi Pasteur should set up compensation and monitoring fund for people administered with the immunization, Sen. …
But investors were not convinced, sending Sanofi’s shares sharply lower on the Paris stock exchange as they wondered about the wisdom of putting so much money on the table. The deal “looks logical, but expensive”, with only modest …
NEW YORK (CNNMoney) -- Sanofi-aventis said Wednesday that it will buy Genzyme ... Genzyme (GENZ, Fortune 500) shares closed Tuesday at $74.30 each. The stock has traded in a range between roughly $72 and $74.50 over the last …
Shares of Sanofi slid last week following news of the company’s bid for takeover of another pharmaceutical company, with shares falling 7 percent to a Friday close of $40.98 per share. Sanofi announced a bid for Medivation, even after the …
Sanofi muscled Novo Nordisk out of the way to buy Ablynx ... Spain's Enagas fell 3.8 per cent after Kepler Cheuvreux cut its target price on the stock.
(on.wsj.com/2mYJulp) The price represents a 64 percent premium to Bioverativ stock’s close on Friday on the Nasdaq. Bioverativ, a hemophilia drug maker, was separated from Biogen Inc early last year. Sanofi has failed to land major …
Sanofi, based in Paris, said it would pay $150 million upfront ... an analyst with Griffin Securities. He estimates MannKind's stock will be trading at $16.25 in one year, nearly twice its Monday closing price. Afrezza is scheduled to …
MannKind Corporation (NASDAQ:MNKD) has finally found a partner to market its diabetes drug Afrezza worldwide. French drugmaker Sanofi SA (ADR) (NYSE:SNY) (EPA:SAN) announced Monday that it would pay MannKind as much as …
Drugmaker Sanofi has suddenly fired its CEO, Chris Viehbacher. The board met early this morning. Bizarrely, Viehbacher's ousting comes in part because he was insufficiently French, it seems: • He was the company's first non …
Sanofi shares were down 2.3 percent in early session trading, making the stock the worst performer on France’s benchmark CAC-40 index. Sanofi also underperformed a flat performance on the STOXX Europe 600 Healthcare index. …